Stereotactic body radiotherapy compared with surgery for localised prostate cancer
Dr Nicholas van As speaks to ecancer at ASCO GU 2022 about PACE-A: An international phase 3 randomised controlled trial comparing stereotactic body radiotherapy (SBRT) with surgery for localised prostate cancer.
He explains that 123 patients were randomised 1:1 between SBRT or surgery with co-primary endpoints of urinary continence (absorbent pads per day) and bowel bother (EPIC bowel subdomain score) at 2 years.
Dr van As reports that with surgery the use of pads was 46% at 2 years and with SBRT it was 4%.
PACE-A contributes the first randomised data to the comparison of SBRT with surgery in localised prostate cancer, providing PRO data relevant to informed decision making.
Compared to surgery, patients receiving SBRT had better urinary continence and sexual bother score; clinician reported GI toxicity was low but SBRT patients reported more bowel bother at 2 years: surgery patients scored 97 and patients in the SBRT arm scored 88.7.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
Видео Stereotactic body radiotherapy compared with surgery for localised prostate cancer канала ecancer
He explains that 123 patients were randomised 1:1 between SBRT or surgery with co-primary endpoints of urinary continence (absorbent pads per day) and bowel bother (EPIC bowel subdomain score) at 2 years.
Dr van As reports that with surgery the use of pads was 46% at 2 years and with SBRT it was 4%.
PACE-A contributes the first randomised data to the comparison of SBRT with surgery in localised prostate cancer, providing PRO data relevant to informed decision making.
Compared to surgery, patients receiving SBRT had better urinary continence and sexual bother score; clinician reported GI toxicity was low but SBRT patients reported more bowel bother at 2 years: surgery patients scored 97 and patients in the SBRT arm scored 88.7.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
ecancer.org/account/register.php
Видео Stereotactic body radiotherapy compared with surgery for localised prostate cancer канала ecancer
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
Management of HER2 positive metastatic breast cancer treatment algorithm
The role of lymph nodes in stage 3 lung cancer
AOH1996 treatment targeting PCNA shows promise for reoccurring solid tumours
Lenvatinib remains standard of care for first-line therapy in advanced hepatocellular carcinoma
Olaparib continues to show positive results in advanced ovarian cancer - 7 year data
Metastatic breast cancer endpoints for survival: rwPFS and TTNT
Treatment algorithm in systemic management of advanced prostate cancer
Low-dose nivolumab leads to improved overall survival for head and neck cancer patients
Glofitamab induces durable complete remissions in patients with relapsed large B-cell lymphoma
LUMINA results: Women with low levels of the Ki67 biomarker can avoid outcomes related to RT
Elacestrant significantly prolongs PFS for ER+/HER2- metastatic BC without prior chemotherapy pts
ASCO 2022: Breast cancer highlights
Comment: LUMINA results show that women with low levels of the Ki67 biomarker can avoid outcomes...
Biomarker guidance allows patients 55 or older with low-grade luminal A-type breast cancer to av...
Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression
Adjuvant endocrine therapy used to treat ER+ HER2- breast cancer
NETs: Capecitabine plus temozolomide gives longer PFS than temozolomide alone
Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients
Neoadjuvant ipilimumab and nivolumab immunotherapy for resectable stage III melanoma
Adagrasib shows CNS penetration and encouraging intracranial activity for KRASG12C-mutated NSCLC